A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 120, Issue 1, 2010, Pages 111-118

  Perez, Alejandra T ^a   Arun, Banu ^b   Tripathy, Debu ^c   Tagliaferri, Mary A ^d   Shaw, Heather S ^e   Kimmick, Gretchen G ^f   Cohen, Isaac ^d   Shtivelman, Emma ^d   Caygill, Katherine A ^d   Grady, Deborah ^g   Schactman, Mark ^h   Shapiro, Charles L ⁱ  

^a Memorial Cancer Institute   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Bionovo Inc   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h University of Iowa   (United States)

ⁱ THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

BZL101; Complementary and alternative medicine; Metastatic breast cancer; Phase 1 clinical trial; Scutellaria barbata

Indexed keywords

ALKALINE PHOSPHATASE; ANTIESTROGEN; BZL 101; PLANT EXTRACT; SCUTELLARIA BARBATA EXTRACT; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOATING; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HUMAN; LIVER METASTASIS; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SCUTELLARIA; SCUTELLARIA BARBATA; SIDE EFFECT; SWEATING; THORAX PAIN; TREATMENT RESPONSE; TUMOR REGRESSION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 74849139728     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0678-5     Document Type: Article

References (14)

1. Horner MJ, Krapcho M, Neyman N et al (eds) (2009) SEER Cancer Statistics Review: 1975-2006. Bethesda, MD, National Cancer Institute, http://seer.cancer. gov/csr/1975-2006/, based on November 2008 SEER data submission, posted to the SEER web site
2. V Guarneri P Conte 2009 Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy Oncologist 14 7 645 656 10.1634/theoncologist.2009-0078 1:CAS:528:DC%2BD1MXhtVOmtrjL 19608638
3. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 783 792 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D 11248153 (Pubitemid 32222155)
4. MJ Campbell B Hamilton M Shoemaker M Tagliaferri I Cohen D Tripathy 2002 Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro Anticancer Res 22 6C 3843 3852 12553004
5. M Shoemaker B Hamilton SH Dairkee I Cohen MJ Campbell 2005 In vitro anticancer activity of twelve Chinese medicinal herbs Phytother Res 19 7 649 651 10.1002/ptr.1702 16161030 (Pubitemid 41375251)
6. S Fong M Shoemaker J Cadaoas, et al. 2008 Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cells Cancer Biol Ther 7 4 577 586 18305410
7. DY Shi FZ Xie C Zhai JS Stern Y Liu SL Liu 2009 The role of cellular oxidative stress in regulating glycolysis energy metabolism in hepatoma cells Mol Cancer 8 32 10.1186/1476-4598-8-32 19497135
8. H Rugo E Shtivelman A Perez, et al. 2007 Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer Breast Cancer Res Treat 105 1 17 28 10.1007/s10549-006-9430-6 1:CAS:528:DC%2BD2sXptFehtbc%3D 17111207 (Pubitemid 47282746)
9. C Le Tourneau JJ Lee LL Siu 2009 Dose escalation methods in phase I cancer clinical trials J Natl Cancer Inst 101 10 708 720 10.1093/jnci/djp079 19436029
10. U.S. Food and Drug Administration: What is a serious adverse event? 8/2009 update. http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm
11. CE Geyer J Forster D Lindquist, et al. 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 26 2733 2743 10.1056/NEJMoa064320 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D 17192538 (Pubitemid 46021510)
12. MS Butler 2004 The role of natural product chemistry in drug discovery J Nat Prod 67 12 2141 2153 10.1021/np040106y 1:CAS:528:DC%2BD2cXhtVSmtLvK 15620274 (Pubitemid 40092578)
13. DJ Newman GM Cragg 2007 Natural products as sources of new drugs over the last 25 years J Nat Prod 70 3 461 477 10.1021/np068054v 1:CAS:528: DC%2BD2sXhvFKrsro%3D 17309302 (Pubitemid 46595760)
14. DJ Newman GM Cragg KM Snader 2003 Natural products as sources of new drugs over the period 1981-2002 J Nat Prod 66 7 1022 1037 10.1021/np030096l 1:CAS:528:DC%2BD3sXksVylu7g%3D 12880330 (Pubitemid 36909859)